Oka Natsuo, Yamamoto Yasuyo, Takahashi Masayuki, Nishitani Masaaki, Kanayama Hiro-Omi, Kagawa Susumu
Department of Urology, The University of Tokushima School of Medicine, Tokushima, Japan.
BJU Int. 2005 Mar;95(4):660-3. doi: 10.1111/j.1464-410X.2005.05358.x.
To investigate the relationship between angiopoietin-1 and -2 expression and the clinicopathological variables and clinical outcome in patients with bladder cancer treated by surgical resection, as both have been recently identified as antagonistic angiogenic factors which regulate tumour growth.
The expression of angiopoietin-1 and -2 were assessed by immunohistochemistry in tissue sections from 52 transitional cell carcinomas of the bladder (33 grade 1, 15 grade 2, four grade 3, including two associated with carcinoma in situ; 22 were stage Ta, 19 T1 and 11 T2 tumours). Normal bladder specimens were also resected during each operation as controls. The expression angiopoietins were related to the clinicopathological variables of the tumours.
Positive immunostaining was detected in 18 samples (35%) for angiopoietin-1 and in 23 (44) for angiopoietin-2. There was no significant difference in survival according to tumour angiopoietin-1 status in the patients, but in contrast the overall survival of patients with angiopoietin-2-positive tumours was significantly lower than for those with angiopoietin-2-negative tumours (P < 0.05). Positive angiopoietin-2 expression was significantly correlated with histological grade (P = 0.026), histological stage (P = 0.009) and poor prognosis (P < 0.05). On multivariate analysis, positive angiopoietin-2 expression was an independent negative predictor for survival (P = 0.042).
These results suggest that angiopoietin-2 overexpression is associated with tumour progression, thereby indicating a poor prognosis for some patients treated by surgical resection for bladder carcinoma.
血管生成素-1和-2最近被确定为调节肿瘤生长的拮抗血管生成因子,本研究旨在探讨手术切除治疗的膀胱癌患者中血管生成素-1和-2的表达与临床病理变量及临床结局之间的关系。
采用免疫组织化学法评估52例膀胱移行细胞癌(33例1级、15例2级、4例3级,其中2例伴有原位癌;22例Ta期、19例T1期和11例T2期肿瘤)组织切片中血管生成素-1和-2的表达。每次手术时还切除正常膀胱标本作为对照。血管生成素的表达与肿瘤的临床病理变量相关。
血管生成素-1在18个样本(35%)中检测到阳性免疫染色,血管生成素-2在23个样本(44%)中检测到阳性免疫染色。患者的生存情况根据肿瘤血管生成素-1状态无显著差异,但相比之下,血管生成素-2阳性肿瘤患者的总生存率显著低于血管生成素-2阴性肿瘤患者(P<0.05)。血管生成素-2阳性表达与组织学分级(P=0.026)、组织学分期(P=0.009)及预后不良(P<0.05)显著相关。多因素分析显示,血管生成素-2阳性表达是生存的独立负性预测因素(P=0.042)。
这些结果表明血管生成素-2过表达与肿瘤进展相关,从而提示一些接受手术切除治疗的膀胱癌患者预后不良。